Table 1 The cardiotoxicity of EGFR-TKIs
From: Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy
Generation | Name | Chemical structure | Targets | Approved for indications on | Cardiotoxicity | Corporation |
|---|---|---|---|---|---|---|
EGFR | ||||||
 First- | Gefitinib (Iressa) |
| EGFR | NSCLC 05/05/2003 | MI, myocarditis, cardiac hypertrophy, AF, left bundle branch block | AstraZeneca |
Erlotinib (Tarceva) |
| EGFR | NSCLC (2004) Pancreatic cancer (2005) | Myocardial ischemic, MI, HF, venous thromboembolism | Roche/Astellas | |
Icotinib (Conmana) |
| EGFR | NSCLC 06/07/2011 | ND | BettaPharma | |
 Second- | Afatinib (Gilotrif) |
| EGFR | NSCLC 07/2013 | diastolic dysfunction, left ventricle enlargement, pericardial effusion | Boehringer Ingelheim |
Dacomitinib (Vizimpro) |
| EGFR | NSCLC 10/2018 | ND | Pfizer | |
 Third- | Osimertinib (Tagrisso) |
| EGFR | NSCLC 11/2015 | Acute coronary syndrome, QT interval prolongation, MI, HF, mitral or tricuspid valve regurgitation, AF, pericardial effusion, decreased LVEF, supraven-tricular tachycardia | AstraZeneca |
Aumonertinib (Ameile) |
| EGFR | NSCLC 2020 | QT interval prolongation | Hansoh | |
Furmonertinib (Alflutinib) |
| EGFR | NSCLC 03/2021 | QT interval prolongation, AF | Allist Pharmaceuticals | |
HER | ||||||
 HER2 | Lapatinib (Tykerb) |
| EGFR/HER2 | Breast cancer 03/2007 | Cardiomyopathy, hypotension, arrhythmia, ischemic heart disease, QT prolongation, decreased LVEF, HF | Novartis |
| Â | Neratinib (Nerlynx) |
| EGFR/HER2/HER4 | Breast cancer 07/2017 | Arrhythmia, ischemic heart disease, QT interval prolongation, decreased LVEF, HF | Puma Biotech |
| Â | Tucatinib (Tukysa) |
| HER2 | HER2-positive breast cancer 04/2020 | ND | Seagen |
| Â | Mobocertinib (Exkivity) |
| EGFR/HER2 | NSCLC 09/2021 | QT interval prolongation, HF | Takeda Pharmaceutical Company |
| Â | Pyrotinib |
| pan-HER | HER2-positive breast cancer 08/2018 | QT interval prolongation | Hengrui Medicine |
